Cargando…

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) involves development of hepatic steatosis, fibrosis, and steatohepatitis. Because hepatic steatosis appears first in NAFLD animal models, the current therapy development focuses on inhibition of hepatic steatosis, suggesting that further steps of NAFLD will b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cast, Ashley, Kumbaji, Meenasri, D'Souza, Amber, Rodriguez, Katherine, Gupta, Anita, Karns, Rebekah, Timchenko, Lubov, Timchenko, Nikolai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671863/ https://www.ncbi.nlm.nih.gov/pubmed/31388625 http://dx.doi.org/10.1002/hep4.1381

Ejemplares similares

Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation
por: D’Souza, Amber M., et al.
Publicado: (2018)

Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin
por: D’Souza, Amber M., et al.
Publicado: (2021)

HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer
por: Rivas, Maria, et al.
Publicado: (2021)

Correction of aging phenotype in the liver
por: Rodriguez, Katherine, et al.
Publicado: (2018)

GSK3β and aging liver
por: Jin, Jingling, et al.
Publicado: (2009)

PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma
por: Valanejad, Leila, et al.
Publicado: (2018)

Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy
por: Lutz, Maggie, et al.
Publicado: (2023)

β‐catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma
por: Gulati, Ruhi, et al.
Publicado: (2022)

Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPα-p300 Axis
por: Nguyen, Phuong, et al.
Publicado: (2018)

GSK3β is a new therapeutic target for myotonic dystrophy type 1
por: Wei, Christina, et al.
Publicado: (2013)

Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma
por: Gulati, Ruhi, et al.
Publicado: (2022)

Molecular signatures of aggressive pediatric liver cancer
por: Johnston, Michael E., et al.
Publicado: (2021)

Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer
por: D’Souza, Amber M., et al.
Publicado: (2022)

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft Models
por: Johnston, Michael Edward, et al.
Publicado: (2021)

Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1
por: Timchenko, Lubov
Publicado: (2019)

Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
por: Timchenko, Lubov
Publicado: (2022)

Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
por: Timchenko, Lubov
Publicado: (2022)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
por: Schoser, Benedikt, et al.
Publicado: (2010)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease
por: Bibbò, Stefano, et al.
Publicado: (2018)

Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
por: Buzzetti, Elena, et al.
Publicado: (2015)

Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease
por: Małecki, Paweł, et al.
Publicado: (2020)

Comment on “Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease”
por: Li, Xia, et al.
Publicado: (2018)

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
por: Cichoż-Lach, Halina, et al.
Publicado: (2012)

Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease
por: Kim, Min Cheol, et al.
Publicado: (2019)

Association between Smoking and Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease
por: Ou, Hongjie, et al.
Publicado: (2019)

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
por: Soon, Gwyneth, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
por: Yu, Jung Hwan, et al.
Publicado: (2023)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease
por: Masugi, Yohei, et al.
Publicado: (2017)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma
por: Timchenko, Nikolai A
Publicado: (2015)

Help for Sick Kids: New Insights Into Hepatoblastoma
por: Timchenko, Nikolai A.
Publicado: (2021)

Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV
por: de Almeida, Cristiane Fonseca, et al.
Publicado: (2021)

The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease
por: Almeda-Valdes, Paloma, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pit0a2tsj47orippc899fb3tk0